Minerva Neurosciences (NERV) EBT (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of EBT data on file, last reported at -$32.3 million in Q1 2026.

• Quarterly EBT fell 762.9% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.0 million (up 61.43% YoY) and the FY2025 annual result came in at -$113.8 million, up 2.4% from the prior year.
• EBT retreated to -$32.3 million in Q1 2026, from -$5.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$2.7 million in Q3 2025 to a low of -$103.7 million in Q4 2023.
• A 5-year average of -$23.6 million and a median of -$6.2 million in 2023 frame the typical range for EBT.
• Annual changes were most pronounced in 2025 — EBT jumped 94.31% — and 2026, when it tumbled 762.9%.
• Tracing NERV's EBT over 5 years: stood at -$94.9 million in 2022, then fell by 9.27% to -$103.7 million in 2023, then climbed by 3.22% to -$100.3 million in 2024, then jumped by 94.31% to -$5.7 million in 2025, then tumbled by 466.37% to -$32.3 million in 2026.
• The last three EBT figures came in at -$32.3 million (Q1 2026), -$5.7 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.